Ashwani Verma

Stock Analyst at UBS

(1.28)
# 1867
Out of 5,370 analysts
78
Total ratings
47.22%
Success rate
3.08%
Average return
23 Stocks
Name Action PT Current % Upside Ratings Updated
ALKS Alkermes
Upgrades: Buy
33 42
30.39 38.2% 5 Jun 17, 2025
INCY Incyte
Maintains: Neutral
61 61
70.43 -13.39% 1 Jun 3, 2025
NBIX Neurocrine Bioscienc...
Maintains: Strong Buy
137 152
124.86 21.74% 8 May 6, 2025
CYTK Cytokinetics
Maintains: Neutral
47 41
33.35 22.94% 5 May 2, 2025
HRMY Harmony Biosciences ...
Maintains: Buy
55 48
32.74 46.61% 2 Apr 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
25 22
22.23 -1.03% 4 Apr 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
2 2
0.76 38.16% 5 Apr 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
145 179
108.53 64.93% 6 Mar 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
30 27
17.07 58.17% 8 Jan 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
30 34
41.76 -18.58% 2 Jan 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
22 14
9.37 49.41% 2 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
415 475
286.37 65.87% 4 Jan 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
106 114
64.69 76.23% 2 Dec 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
55 54
15.01 259.76% 3 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
83 79
n/a n/a 5 Aug 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
107 105
100.33 4.65% 2 Aug 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
28
34.83 -19.61% 3 Jun 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
76 81
34.49 134.85% 2 Mar 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
11 7
81.56 -91.42% 1 Aug 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
209
n/a n/a 2 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
9 12
8.88 35.14% 2 Nov 10, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
15
0.55 2627.27% 1 Oct 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
137 71
n/a n/a 3 Aug 4, 2022